By Adriano Marchese
Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin to be used in conjunction with Merck's Keytruda after results showed no statistical improvement in survival.
The clinical-stage immuno-oncology company said Tuesday that it won't continue to final analysis and cease development of nemvaleukin, its drug that was aimed to treat platinum-resistant ovarian cancer.
This particular ovarian cancer is resistant to platinum-based chemotherapy treatments which are commonly the first option.
Mural Oncology said the Artistry-7 phase 3 trial of nemvaleukin alfa in combination with Merck's anti-PD-1 therapy, Keytruda, didn't achieve a statistically significant improvement in overall survival compared with chemotherapy alone.
Shares of Mural were over 26% lower in premarket trading at $2.82.
The treatment is still being evaluated in a phase 2 trial to treat mucosal melanoma. The company said it expects to share its data readout in the second quarter.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
March 25, 2025 07:08 ET (11:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.